These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38651109)

  • 1. Response assessment of GBM during immunotherapy by delayed contrast treatment response assessment maps.
    Cuccarini V; Savoldi F; Mardor Y; Last D; Pellegatta S; Mazzi F; Bruzzone MG; Anghileri E; Pollo B; Maddaloni L; Russo C; Bocchi E; Pinzi V; Eoli M; Aquino D
    Front Neurol; 2024; 15():1374737. PubMed ID: 38651109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DC-AL GAN: Pseudoprogression and true tumor progression of glioblastoma multiform image classification based on DCGAN and AlexNet.
    Li M; Tang H; Chan MD; Zhou X; Qian X
    Med Phys; 2020 Mar; 47(3):1139-1150. PubMed ID: 31885094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment Against Glioblastoma.
    Cuccarini V; Aquino D; Gioppo A; Anghileri E; Pellegatta S; Schettino C; Mazzi F; Finocchiaro G; Bruzzone MG; Eoli M
    J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31744235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
    Xi J; Hassan B; Katumba RGN; Khaddour K; Govindan A; Luo J; Huang J; Campian JL
    BMC Cancer; 2021 Mar; 21(1):285. PubMed ID: 33726710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stratification of pseudoprogression and true progression of glioblastoma multiform based on longitudinal diffusion tensor imaging without segmentation.
    Qian X; Tan H; Zhang J; Zhao W; Chan MD; Zhou X
    Med Phys; 2016 Nov; 43(11):5889. PubMed ID: 27806598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.
    Rowe LS; Butman JA; Mackey M; Shih JH; Cooley-Zgela T; Ning H; Gilbert MR; Smart DK; Camphausen K; Krauze AV
    J Neurooncol; 2018 Aug; 139(1):145-152. PubMed ID: 29767308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis.
    Sidibe I; Tensaouti F; Gilhodes J; Cabarrou B; Filleron T; Desmoulin F; Ken S; Noël G; Truc G; Sunyach MP; Charissoux M; Magné N; Lotterie JA; Roques M; Péran P; Cohen-Jonathan Moyal E; Laprie A
    Radiother Oncol; 2023 Apr; 181():109486. PubMed ID: 36706959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Use of Treatment Response Assessment Maps in Discriminating Between Radiation Effect and Persistent Tumoral Lesion in Metastatic Brain Tumors Treated with Gamma Knife Radiosurgery.
    Peker S; Samanci Y; Aygun MS; Yavuz F; Erden ME; Nokay AE; Atasoy Aİ; Bolukbasi Y
    World Neurosurg; 2021 Feb; 146():e1134-e1146. PubMed ID: 33253956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.
    Kebir S; Fimmers R; Galldiks N; Schäfer N; Mack F; Schaub C; Stuplich M; Niessen M; Tzaridis T; Simon M; Stoffels G; Langen KJ; Scheffler B; Glas M; Herrlinger U
    Clin Cancer Res; 2016 May; 22(9):2190-6. PubMed ID: 26673798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI Treatment Response Assessment Maps (TRAMs) for differentiating recurrent glioblastoma from radiation necrosis.
    Müller SJ; Khadhraoui E; Ganslandt O; Henkes H; Gihr GA
    J Neurooncol; 2024 Feb; 166(3):513-521. PubMed ID: 38261142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A deep learning model for discriminating true progression from pseudoprogression in glioblastoma patients.
    Moassefi M; Faghani S; Conte GM; Kowalchuk RO; Vahdati S; Crompton DJ; Perez-Vega C; Cabreja RAD; Vora SA; Quiñones-Hinojosa A; Parney IF; Trifiletti DM; Erickson BJ
    J Neurooncol; 2022 Sep; 159(2):447-455. PubMed ID: 35852738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma.
    Verma G; Chawla S; Mohan S; Wang S; Nasrallah M; Sheriff S; Desai A; Brem S; O'Rourke DM; Wolf RL; Maudsley AA; Poptani H
    NMR Biomed; 2019 Feb; 32(2):e4042. PubMed ID: 30556932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guideline conformity to the Stupp regimen in patients with newly diagnosed glioblastoma multiforme in China.
    Wang Y; Zhang J; Li W; Jiang T; Qi S; Chen Z; Kang J; Huo L; Wang Y; Zhuge Q; Gao G; Wu Y; Feng H; Zhao G; Yang X; Zhao H; Wang Y; Yang H; Kang D; Su J; Li L; Jiang C; Li G; Qiu Y; Wang W; Wang H; Xu Z; Zhang L; Wang R
    Future Oncol; 2021 Nov; 17(33):4571-4582. PubMed ID: 34519220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas.
    de Godoy LL; Mohan S; Wang S; Nasrallah MP; Sakai Y; O'Rourke DM; Bagley S; Desai A; Loevner LA; Poptani H; Chawla S
    J Transl Med; 2023 Apr; 21(1):287. PubMed ID: 37118754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed contrast extravasation MRI: a new paradigm in neuro-oncology.
    Zach L; Guez D; Last D; Daniels D; Grober Y; Nissim O; Hoffmann C; Nass D; Talianski A; Spiegelmann R; Tsarfaty G; Salomon S; Hadani M; Kanner A; Blumenthal DT; Bukstein F; Yalon M; Zauberman J; Roth J; Shoshan Y; Fridman E; Wygoda M; Limon D; Tzuk T; Cohen ZR; Mardor Y
    Neuro Oncol; 2015 Mar; 17(3):457-65. PubMed ID: 25452395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
    Pinho MC; Polaskova P; Kalpathy-Cramer J; Jennings D; Emblem KE; Jain RK; Rosen BR; Wen PY; Sorensen AG; Batchelor TT; Gerstner ER
    Oncologist; 2014 Jan; 19(1):75-81. PubMed ID: 24309981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Inflammation Response Index Predicts Survival Outcomes in Glioblastoma Multiforme Patients Treated with Standard Stupp Protocol.
    Topkan E; Kucuk A; Ozdemir Y; Mertsoylu H; Besen AA; Sezen D; Bolukbasi Y; Pehlivan B; Selek U
    J Immunol Res; 2020; 2020():8628540. PubMed ID: 33274245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
    Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation.
    Hagiwara A; Schlossman J; Shabani S; Raymond C; Tatekawa H; Abrey LE; Garcia J; Chinot O; Saran F; Nishikawa R; Henriksson R; Mason WP; Wick W; Cloughesy TF; Ellingson BM
    J Neurooncol; 2022 Sep; 159(3):509-518. PubMed ID: 35842871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.